Press releases
- Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
- Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
- Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
- Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
More ▼
Key statistics
On Wednesday, Relmada Therapeutics Inc (4E2:MUN) closed at 3.02, 34.82% above the 52 week low of 2.24 set on Jun 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.02 |
---|---|
High | 3.02 |
Low | 3.02 |
Bid | 2.84 |
Offer | 2.90 |
Previous close | 3.02 |
Average volume | 0.00 |
---|---|
Shares outstanding | 30.17m |
Free float | 27.75m |
P/E (TTM) | -- |
Market cap | 97.76m USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of May 22 2024 07:01 BST.
More ▼